1. Bagri A, Berry L, Gunter B, Singh M, Kasman I, Damico LA, Xiang H, Schmidt M, Fuh G, Hollister B, Rosen O, Plowman GD (2010) Effects of anti-VEGF treatment duration on tumor growth, tumor regrowth, and treatment efficacy. Clin Cancer Res 16: 3887–3900
2. Bamberger ES, Perrett CW (2002) Angiogenesis in epithelial ovarian cancer. Mol Pathol 55: 348–359
3. Bani MR, Nicoletti MI, Alkharouf NW, Ghilardi C, Petersen D, Erba E, Sausville EA, Liu ET, Giavazzi R (2004) Gene expression correlating with response to paclitaxel in ovarian carcinoma xenografts. Mol Cancer Ther 3: 111–121
4. Barton DP, Cai A, Wendt K, Young M, Gamero A, De Cesare S (1997) Angiogenic protein expression in advanced epithelial ovarian cancer. Clin Cancer Res 3: 1579–1586
5. Belotti D, Vergani V, Drudis T, Borsotti P, Pitelli MR, Viale G, Giavazzi R, Taraboletti G (1996) The microtubule-affecting drug paclitaxel has antiangiogenic activity. Clin Cancer Res 2: 1843–1849